Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition

BACKGROUND: Immune checkpoint inhibitors (ICIs) for solid tumors, including those targeting programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have shown impressive clinical efficacy, however, most patients do not achieve durable responses. One major therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Newton, Jared M., Hanoteau, Aurelie, Liu, Hsuan-Chen, Gaspero, Angelina, Parikh, Falguni, Gartrell-Corrado, Robyn D., Hart, Thomas D., Laoui, Damya, Van Ginderachter, Jo A., Dharmaraj, Neeraja, Spanos, William C., Saenger, Yvonne, Young, Simon, Sikora, Andrew G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693252/
https://www.ncbi.nlm.nih.gov/pubmed/31409394
http://dx.doi.org/10.1186/s40425-019-0698-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693252/
https://www.ncbi.nlm.nih.gov/pubmed/31409394
http://dx.doi.org/10.1186/s40425-019-0698-6

Ejemplares similares